Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...

About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

With the completion of the successful Phase 3 VERITAC-2 trial, in June 2025 Pfizer and Arvinas filed an NDA seeking FDA approval.

This submission follows positive Phase 3 trial results from the VERITAC-2 study, which highlighted the drug’s efficacy against fulvestrant. The study’s findings were presented at the American Society ...

This submission follows promising results from the Phase 3 VERITAC-2 trial, which showed a median progression-free survival of five months for vepdegestrant compared to 2.1 months in the control group ...

This submission follows positive Phase 3 trial results from the VERITAC-2 study, which highlighted the drug’s efficacy against fulvestrant.

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and ...